LSV Asset Management Increases Stake in Cambrex Co. (CBM)

LSV Asset Management grew its stake in shares of Cambrex Co. (NYSE:CBM) by 6.5% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 66,850 shares of the biotechnology company’s stock after purchasing an additional 4,100 shares during the period. LSV Asset Management owned approximately 0.20% of Cambrex worth $3,496,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors also recently made changes to their positions in the company. William Blair Investment Management LLC raised its holdings in shares of Cambrex by 35.8% during the fourth quarter. William Blair Investment Management LLC now owns 2,353,032 shares of the biotechnology company’s stock valued at $112,946,000 after purchasing an additional 620,098 shares during the period. Congress Asset Management Co. MA raised its holdings in shares of Cambrex by 4.2% during the fourth quarter. Congress Asset Management Co. MA now owns 1,482,826 shares of the biotechnology company’s stock valued at $71,176,000 after purchasing an additional 59,600 shares during the period. Brown Advisory Inc. raised its holdings in shares of Cambrex by 454.1% during the fourth quarter. Brown Advisory Inc. now owns 895,240 shares of the biotechnology company’s stock valued at $42,972,000 after purchasing an additional 733,663 shares during the period. Boston Partners raised its holdings in shares of Cambrex by 118.5% during the fourth quarter. Boston Partners now owns 709,786 shares of the biotechnology company’s stock valued at $34,069,000 after purchasing an additional 384,897 shares during the period. Finally, American Capital Management Inc. raised its holdings in shares of Cambrex by 16.4% during the fourth quarter. American Capital Management Inc. now owns 658,644 shares of the biotechnology company’s stock valued at $31,615,000 after purchasing an additional 92,986 shares during the period.

In other Cambrex news, COO Shawn Cavanagh sold 40,000 shares of the company’s stock in a transaction dated Tuesday, May 8th. The shares were sold at an average price of $49.69, for a total value of $1,987,600.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Gregory Sargen sold 67,500 shares of the company’s stock in a transaction dated Tuesday, May 8th. The stock was sold at an average price of $49.48, for a total transaction of $3,339,900.00. The disclosure for this sale can be found here. Insiders own 2.42% of the company’s stock.

NYSE:CBM opened at $47.90 on Tuesday. The stock has a market cap of $1.58 billion, a PE ratio of 14.48, a price-to-earnings-growth ratio of 1.17 and a beta of 2.34. Cambrex Co. has a one year low of $42.55 and a one year high of $62.30.

Cambrex (NYSE:CBM) last posted its earnings results on Thursday, May 3rd. The biotechnology company reported $0.72 EPS for the quarter, topping the consensus estimate of $0.50 by $0.22. The company had revenue of $141.10 million during the quarter, compared to the consensus estimate of $104.44 million. Cambrex had a net margin of 18.69% and a return on equity of 21.00%. The firm’s revenue for the quarter was up 34.4% on a year-over-year basis. During the same period in the previous year, the firm posted $0.68 earnings per share. research analysts anticipate that Cambrex Co. will post 2.73 EPS for the current year.

CBM has been the subject of several recent research reports. Zacks Investment Research raised shares of Cambrex from a “sell” rating to a “hold” rating in a research report on Wednesday, April 11th. Longbow Research downgraded shares of Cambrex from a “buy” rating to a “neutral” rating in a research report on Wednesday, February 14th. Finally, ValuEngine downgraded shares of Cambrex from a “hold” rating to a “sell” rating in a research report on Thursday, May 3rd. Two analysts have rated the stock with a sell rating, two have given a hold rating and two have issued a buy rating to the company’s stock. Cambrex presently has an average rating of “Hold” and an average target price of $60.00.

Cambrex Profile

Cambrex Corporation, a life sciences company, provides various products and services for the development and commercialization of new and generic therapeutics worldwide. Its products comprise active pharmaceutical ingredients and pharmaceutical intermediates that are used in the production of prescription and over-the-counter drug products, as well as other fine chemicals.

Want to see what other hedge funds are holding CBM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cambrex Co. (NYSE:CBM).

Institutional Ownership by Quarter for Cambrex (NYSE:CBM)

Receive News & Ratings for Cambrex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cambrex and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply